Skip to main content

Table 1 Study population characteristics by inclusion status

From: The impact of HCV co-infection status on healthcare-related utilization among people living with HIV in British Columbia, Canada: a retrospective cohort study

Variables

Overall

Included

Excluded

P-value

N = 4217

N = 3955

N = 262

Sex, n(%)

    

 Female

805 (19)

735 (91)

70 (9)

0.0016

 Male

3412 (81)

3220 (94)

192 (6)

 

Status

    

 HIV mono-infected

2333 (55)

2333 (100)

0 (0)

NA

 HIV/HCV co-infected

1622 (39)

1622 (100)

0 (0)

 

 Unknown

262 (6)

0 (0)

262 (100)

 

Age at ART initiation (years), n (%)

    

 <  30

516 (12)

481 (93)

35 (7)

0.1724

 30–39

1294 (31)

1216 (94)

78 (6)

 

 40–49

1523 (36)

1441 (95)

82 (5)

 

 ≥ 50

884 (21)

817 (92)

67 (8)

 

Risk, n(%)

    

 MSM

1376 (33)

1294 (94)

82 (6)

< 0.0001

 PWID

1335 (32)

1298 (97)

37 (3)

 

 MSM/ PWID

314 (7)

309 (98)

5 (2)

 

 Other

652 (15)

581 (89)

71 (11)

 

 Unknown

540 (13)

473 (88)

67 (12)

 

ART era, n(%)

    

 2000–2003

859 (20)

797 (93)

62 (7)

0.1037

 2004–2007

1214 (29)

1153 (95)

61 (5)

 

 2008–2011

1704 (40)

1599 (94)

105 (6)

 

 2012–2013

440 (10)

406 (92)

34 (8)

 

Baseline CD4 cell count (cells/mm3), n (%)

    

 <  50

498 (12)

474 (95)

24 (5)

0.4136

 50–199

1366 (32)

1285 (94)

81 (6)

 

 200–349

1329 (32)

1238 (93)

91 (7)

 

 ≥ 350

1024 (24)

958 (94)

66 (6)

 

ART Adherence (first six months), n (%)

    

 ≥ 95%

3291 (78)

3084 (94)

207 (6)

0.7563

 80–94%

218 (5)

208 (95)

10 (5)

 

 40–79%

474 (11)

445 (94)

29 (6)

 

 <  40%

234 (6)

218 (93)

16 (7)

 

Number of comorbidities at baseline, n(%)

    

 0

1451 (34)

1357 (94)

94 (6)

0.8122

 1

1397 (33)

1307 (94)

90 (6)

 

 2

768 (18)

725 (94)

43 (6)

 

 ≥3

601 (14)

566 (94)

35 (6)

 

Initial ART regimen, n(%)

    

 NNRTI

2033 (48)

1895 (93)

138 (7)

0.1531

 bPI

2184 (52)

2060 (94)

124 (6)

 

Total healthcare-related visits, median (Q1-Q3)

97 (48–187)

99 (49–191)

71 (31–125)

< 0.0001

Baseline viral load (log10 copies/mL), median (Q1-Q3)

4.90 (4.38–5.00)

4.90 (4.38–5.00)

4.85 (4.28–5.00)

0.4339

Follow-up time (years), median (Q1-Q3)

4.99 (2.50–7.98)

4.99 (2.81–8.00)

3.50 (1.76–5.99)

< 0.0001

  1. Q1-Q3: 25th - 75th percentiles; MSM: Gay, bisexual and other men who have sex with men; PWID: people who have ever injected drugs; ART: combination antiretroviral therapy; NNRTI: non-nucleoside reverse transcriptase inhibitor; bPI: ritonavir-boosted protease inhibitor; NA: not applicable. Note that Overall column shows column percent, while Included/Excluded columns show row percent
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us